Wegovy results: when do you see them, and what shapes the timeline?

Step 1, weeks one to four: the body adjusts, appetite shifts first

The opening pen of Wegovy contains the 0.25 mg starting dose. Its job is tolerability, not dramatic weight loss. What most people do notice in this first month is a quieter appetite: meals that used to feel routine start feeling like enough sooner than expected. Some people describe eating two-thirds of a plate and simply stopping. That shift is the medicine's GLP-1 receptor activity beginning to work, slowing gastric emptying and dampening hunger signals in the brain.

At this stage, the scale may not move much, or at all. That is normal. A question our prescribers hear regularly is whether the medicine is working if the number hasn't budged by week three. It almost certainly is, the starter dose is designed to settle your system before the therapeutic work begins. Patience here pays off in fewer side effects later.

Practical routine often helps. Many people find it easiest to take their weekly injection on the same day each week, some pair it with a calendar habit, others keep the pen at the front of the fridge alongside everyday items so it's never forgotten. Small habits matter when you're months into a treatment plan.

Step 2, weeks four to sixteen: titration and early weight loss

Every four weeks, a prescriber reviews your progress and, if you're tolerating the current dose well, the next step begins: 0.5 mg, then 1.0 mg, then 1.7 mg. This is the period when most people start to see measurable changes on the scales. Appetite suppression becomes more consistent, the sense of fullness after smaller meals is more pronounced, and the cumulative calorie reduction starts showing.

Data from the STEP 1 trial, published in the New England Journal of Medicine, showed that participants had lost roughly 5–8% of their body weight on average by around week 16, well before reaching the 2.4 mg maintenance dose. That early momentum tends to build confidence, but it is worth knowing that the rate of loss often slows as the body adapts and as calorie intake stabilises at its new lower level.

Side effects are most common during a dose increase: nausea, loose stools or constipation, and occasional fatigue. These are usually mild and settle within a week or two. For a thorough breakdown of how long Wegovy takes to work at each stage, including what to do if you feel the titration is too fast, the answer is always the same: speak to your prescriber before changing anything.

Step 3, week sixteen onward: the maintenance dose and sustained loss

Once established at 2.4 mg (or 7.2 mg, where appropriate and prescribed), Wegovy's full effect becomes clearer. The STEP 1 trial's headline average of around 15% body weight reduction over 68 weeks was achieved primarily during this phase, a significant portion of total loss accumulates in months four through seventeen, not month one. Weight loss at maintenance is slower than in some people's expectations, but it is also more durable.

The MHRA approved a 7.2 mg single-dose Wegovy pen in April 2026, and the approval announcement on GOV.UK noted average weight loss of around 20.7% over 72 weeks in the supporting trials, a meaningful step above the 2.4 mg maintenance figure, and one that narrows the gap with tirzepatide results. That dose is available only for adults with a BMI of 30 or above, and suitability is a clinical decision made with your prescriber.

For anyone wondering specifically when weight loss on Wegovy becomes visible to others, the honest answer is: it varies. A 5% reduction in a person weighing 100 kg is five kilograms. That is often noticeable to the individual well before it is obvious to others. Clothes tend to tell the story before mirrors or comments do.

What affects the pace of your results?

The trial averages are population figures. Individuals vary considerably, and several factors influence where on the curve you land. Starting BMI plays a role: people with higher starting weights often see larger absolute losses, though percentage loss tends to be similar. Adherence to the titration schedule matters, as does the dietary shift, semaglutide reduces appetite but does not override nutrition; adequate protein, hydration and fibre all support the process. Activity levels, particularly resistance training, help preserve muscle while fat reduces.

Underlying metabolic health is relevant too. People with type 2 diabetes, for instance, typically see slightly smaller weight reductions than people without diabetes on the same dose, as noted in Wegovy's trial programme. Sleep, stress and other medications can all interact with the trajectory. For a broader view of how long results take on Wegovy across different starting situations, the picture is nuanced, which is exactly why a prescriber reviews your individual circumstances before and during treatment. If you have questions about when you start to see results from Wegovy at each stage of the titration, or want to understand when you start seeing results on Wegovy in terms of appetite changes versus scale changes, both are covered in detail to help set realistic expectations.

Wegovy is a prescription-only medicine, and its results are tied to consistent, clinically supervised use. If you're considering it, the full Wegovy overview covers eligibility, how the treatment works, and what the NHS and private routes look like in practice. You can also explore other licensed weight-loss treatment options if you're comparing approaches. When you're ready to take the next step, start your free consultation with our prescribers, reviewed the same day, by a real clinician, not a system.